XC221

DRUG4 trials

Sponsors

PHARMENTERPRISES LLC, RSV Therapeutics LLC, Valenta Pharm JSC

Conditions

Acute Respiratory Viral InfectionsInfluenzaRespiratory Viral InfectionSARS-CoV-2 InfectionSars-CoV-2 Infection

Phase 2

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

CompletedNCT03830905

PHARMENTERPRISES LLCAcute Respiratory Viral Infections, Influenza

Start: 2019-01-31End: 2019-07-03Updated: 2020-11-16

Phase 3

A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19

CompletedNCT04487574

RSV Therapeutics LLCSARS-CoV-2 Infection

Start: 2020-07-25End: 2020-10-29Updated: 2023-07-27

A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19

CompletedNCT04940182

RSV Therapeutics LLCSars-CoV-2 Infection

Start: 2021-06-26End: 2022-11-14Updated: 2023-07-27

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

CompletedNCT05544916

Valenta Pharm JSCInfluenza, Respiratory Viral Infection

Start: 2022-08-05End: 2023-05-04Updated: 2023-10-10